Anti-CD3-anti-SCLC bispecific monoclonal antibody

Drug Profile

Anti-CD3-anti-SCLC bispecific monoclonal antibody

Alternative Names: Anti-CD3-anti-SCLC monoclonal antibody; OKT3-LU246 bispecific monoclonal antibody

Latest Information Update: 02 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Small cell lung cancer

Most Recent Events

  • 02 Jul 1998 Profile reviewed
  • 02 Jul 1998 No-Development-Reported for Small cell lung cancer in Japan (Unknown route)
  • 28 May 1996 Preclinical development for Small cell lung cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top